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ABSTRACT: Triclinic calcium pyrophosphate dihydrate (t-
CPPD) crystals are one of the two polymorphs of micro-
crystals that have been found in the joints of patients suﬀering
from pseudogout. However, there is currently no treatment for
inhibiting the formation of these crystals, which present a high
inﬂammatory potential. In this context we studied in vitro the
precipitation of t-CPPD in a stirred reactor under pH- and
temperature-controlled conditions and determined the eﬀect
of selected biologically relevant ionic additives (Mg2+, Cu2+,
Fe3+, Zn2+, S2O3
2−) on its formation. The results showed that 1
mM Fe3+, Zn2+, or Cu2+ induced the most signiﬁcant changes
by partly inhibiting the crystallization of t-CPPD and favoring
the formation of an amorphous-CPP phase (98 wt %) in the presence of Fe3+ or a monoclinic-CPPD phase (78 or 71 wt %,
respectively) in the presence of Zn2+ or Cu2+. Correlations between 31P solid-state NMR, XRD, and elemental analyses showed
that the additive cations are inserted into the monoclinic-CPPD and/or amorphous-CPP phases. This study, which combines
structural, morphological, and elemental analyses, paves the way toward a deeper comprehension of the role of ionic additives in
preventing the formation of CPPD crystalline phases, and is a key step in long-term development of an eﬀective therapeutic
treatment.
1. INTRODUCTION
Osteoarthritis (OA) and pseudogout are forms of arthritis
involving the deposition of microcrystals in the joints. Hydrated
calcium pyrophosphates (CPP: Ca2P2O7·nH2O) have been
identiﬁed among the deposited microcrystals in the joints of
arthritic patients. More precisely, two polymorphs of CPP
dihydrate (CPPD: Ca2P2O7·2H2O) have been found in the
joint tissues (cartilage, meniscus) or synovial ﬂuids of patients
suﬀering from pseudogout: the monoclinic (m-CPPD) and
triclinic (t-CPPD) phases which both present a high
inﬂammatory potential.1,2 The triclinic form is considered the
most stable and is the most commonly found in vitro and in
vivo.3−5 There is currently no treatment that inhibits the
formation of these CPP crystals, but only treatment helping to
limit the inﬂammatory response and relieve the patient’s pain.6,7
Understanding the mechanisms of formation of CPP in vitro
and in vivo and the inﬂuence of substances that could
potentially inhibit the crystallization of the m-CPPD and t-
CPPD phases is a key step in the medium- to long-term
development of an eﬀective therapeutic treatment.
Although only two dihydrated forms of CPPD crystals have
been detected in vivo (m- and t-CPPD), investigations of other
hydrated forms, such as the tetrahydrated CPP (m-CPPT β:
Ca2P2O7·4H2O) and especially amorphous CPP (a-CPP:
Ca2P2O7·nH2O with n ≅ 3 to 4), have also been reported in
vitro;8−10 these phases are also of interest as potential precursor
phases for the crystalline t- and m-CPPD phases in vitro and in
vivo.
There are few studies in the literature on CPP precipitation
in the presence of additives.11−15 In addition, these
experimental studies did not provide explanations of the
mechanism by which the additives act on the crystallization of
diﬀerent CPP phases. However, the inﬂuence of additives or
impurities on the crystallization of other compounds has been
extensively studied in previous work.16,17 It is known that
additives can act in diﬀerent ways: they can favor the formation
of one phase at the expense of another,18 they can increase the
nucleation rate at the expense of the growth step, or they can
selectively inhibit or promote the growth of particular crystal
faces.19
In the case of CPP precipitation, one can classify the
potential additives into diﬀerent categories: (i) additives having
a chemical resemblance to pyrophosphate or orthophosphate
ions, such as phosphocitrates20 and bisphosphonates;21 (ii)
proteins of biological interest, such as osteopontin, a negatively
charged bone sialoprotein22 and fetuin A, a blood protein;23
and (iii) cationic additives corresponding to ions already found
in the body, such as Mg2+ or Fe3+.
These additives may act according to the modes of action
described by Mullin24 and Nyvlt and Ulrich.25 Diﬀerent
adsorption sites exist on the crystal surface (kinks, steps, and
edges) and the additive can be adsorbed on one or more of
these sites, to create a complex compound with entities/ions at
the surface of the crystal or included in the crystal lattice. This
can be facilitated if there is a similarity of ionic or molecular
structure between the additive and the ions or molecules
constituting the crystal (i.e., P2O7
4− and/or Ca2+ in the case of
CPPD compounds). In the present study, only ionic additives
will be considered.
Cheng and Pritzker14 showed that magnesium ions promote
the production of crystals of the m-CPPD phase rather than t-
CPPD in a laboratory study where the concentrations of Ca2+
and Mg2+ were varied simultaneously during the synthesis of
CPP. These authors performed their tests with three diﬀerent
concentrations of sodium pyrophosphate high enough to obtain
suﬃcient CPP precipitate for analysis. Mandel et al. reported a
synthesis protocol of m-CPPD involving magnesium ions
which were not present in the synthesis of t-CPPD.26
In our study, besides Mg2+, four other types of biologically
relevant ions (Zn2+, Cu2+, Fe3+, and S2O3
2−) were selected as
additives. In human metabolism, iron is present in two diﬀerent
ionic forms: Fe2+ (ferrous) and Fe3+ (ferric). Fe2+ is transported
in the blood by ferroportin, but the element is taken up in
tissues and cells as Fe3+, using transferrin (a plasmatic carrier)
and ferritin (an intracellular storage protein).27 In addition, it is
known that iron and magnesium are associated with
hypomagnesaemia and hemochromatosis diseases which are
related to premature osteoarthritis.28,29 In hemochromatosis
joint disease, measurements of serum ferritin have proven to be
useful in disease detection.30 Furthermore, previous studies on
crystal growth have shown that the higher the charge state of
the ion is, the more pronounced is the eﬀect of this ion on
crystallization.24 Indeed, if Fe2+ were used in this study, it
would be diﬃcult to stabilize and to prevent its oxidization in
solution at high temperature (e.g., 90 °C) and acidic pH.
Therefore, Fe3+ was chosen in the present study.
Among the other ions of interest, thiosulfate (S2O3
2−) was
previously studied and displayed a reasonable eﬃciency in the
treatment of renal or vascular calciﬁcations.31−33 This ion was
selected to determine its inﬂuence, if any, on the formation of
CPP involved in osteoarthritis.
The objective of this study is to synthesize t-CPPD in vitro
through a precipitation process in a stirred reactor under pH-
and temperature-controlled conditions and to determine the
eﬀect of the selected ionic additives on its precipitation. We do
not intend on mimicking in vivo conditions for CPPD
polymorph precipitation (it seems diﬃcult at this stage,
owing to the lack of information we have on these systems at
the onset of CPPD formation) but we aim to evaluate and
compare the eﬀect of various biologically relevant ionic
additives while keeping all the other synthesis parameters
identical to the t-CPPD reference synthesis (without additive).
The eﬀect of these diﬀerent ions will be thoroughly
investigated by means of a set of complementary character-
ization techniques: X-ray diﬀraction, Fourier-transform infrared
(FTIR) spectroscopy, Raman spectroscopy, solid-state nuclear
magnetic resonance (solid-state NMR), scanning electron
microscopy, and elemental analysis by inductively coupled
plasma spectrometry.
2. MATERIALS AND METHODS
2.1. Materials. Anhydrous potassium pyrophosphate (K4P2O7)
was obtained by heating potassium hydrogen phosphate dihydrate
(K2HPO4·2H2O, VWR, purity: 100%) at 400 °C for 4 h, and was used
to prepare the pyrophosphate reagent solution (rs). The other
precipitating reagents, i.e., calcium nitrate tetrahydrate (Ca(NO3)2·
4H2O, Carlo Erba, purity: 97%), acetic acid (VWR, purity: 100%), and
ammonia aqueous solution (VWR, 30%), were used without
undergoing further puriﬁcation.
Commercial salts of zinc acetate dihydrate (Zn(CH3COO)2·2H2O,
Fisher Scientiﬁc, purity: 99.5%), iron chloride hexahydrate (FeCl3·
6H2O, VWR, purity: 98%), magnesium chloride hexahydrate (MgCl2·
6H2O, VWR, purity: 100%), copper nitrate hydrate (Cu(NO3)2·
2.5H2O, Alfa Aesar, purity: 98%), and sodium thiosulfate pentahydrate
(Na2S2O3·5H2O, VWR Prolabo, purity: 99.5%) were used as additives.
All the solutions used for performing precipitation by the double
decomposition method were prepared by dissolving the salts in
ultrapure water (18.2 MΩ.cm).
2.2. Experimental Setup for Precipitation in the Absence or
Presence of Ionic Additive. Pure t-CPPD, m-CPPD, and a-CPP
reference samples for this study, i.e., without any additive, were
synthesized by double decomposition precipitation by simultaneously
adding, at controlled ﬂow rate (2.25 mL.min−1), a potassium
pyrophosphate reagent solution (rs) and a calcium nitrate reagent
solution (rs) into an ammonium acetate buﬀer solution (b) at
controlled temperature and pH. This method of synthesis was adapted
from that published by Gras et al.10 and implemented in a stirred
reactor in order to study the eﬀect of the ionic additives under
improved control of conditions (pH, temperature, and stirring/
mixing). The pure CPP phase obtained by this method depends on the
chosen combination of pH and temperature as reported in Table 1.
The precipitation reaction involved in the precipitation of the t-
CPPD or m-CPPD phase is
+ + → ·
+ −
2 Ca P O 2 H O Ca P O 2H O
2
2 7
4
2 2 2 7 2
Reagent solutions were prepared at room temperature by dissolving
K4P2O7 (8.70 × 10
−3 mol) or Ca(NO3)2·4H2O (1.74 × 10
−2 mol) in
115 mL of ultrapure water to respectively prepare the pyrophosphate
and calcium reagent solutions (rs). A buﬀer solution (b) of ammonium
acetate was prepared from a mixture of acetic acid and ammonia in
water: mmonia solution was poured into the acetic acid solution to
reach the desired pH (i.e., 3.6 for t-CPPD and 5.8 for m-CPPD or a-
CPP).
The experiments were carried out in a 500 mL double-jacketed
Pyrex glass round-bottomed crystallizer. This tank was equipped with
four baﬄes, a lid, and a pH probe (PHC3001−8 Radiometer
Analytical) connected to a pH-meter (PHM220 Radiometer
Table 1. Selected Temperature and pH Conditions for the
Synthesis of the Various Pure Reference CPP Phases
According to Gras et al.10
CPP phase synthesized t-CPPD m-CPPD a-CPP
Temperature 90 °C 90 °C 25 °C
pH 3.6 5.8 5.8
Analytical). Temperature control was provided by a cryostat (AD15R-
30, VWR) connected to an external temperature sensor (PT100,
VWR). A stirrer (Propeller Stirrer Shafts, Bola) ﬁxed to a motor (RW
20 digital, IKA) was used to ensure a homogeneous mixture. 100 mL
of the cationic and anionic reagent solutions were simultaneously
added at a constant ﬂow rate (2.25 mL.min−1) in the buﬀer solution
(200 mL) by means of two syringe pumps (Harvard Apparatus PHD
2000) (Figure 1). At the end of the addition of the reagent solutions,
an aging step was performed at the selected temperature (90 °C for m-
CPPD and t-CPPD or 25 °C for a-CPP precipitation) for 10 min
under stirring. The precipitate was then ﬁltered on a Buchner funnel
and washed with 1200 mL of deionized water before being dried in an
oven at 37 °C for at least 12 h. Finally, the samples obtained were
stored at ambient temperature in a sealed container to avoid any
contamination.
The eﬀect of various ionic additives (A) on t-CPPD precipitation
was investigated at 90 °C and pH 3.6, i.e., the combination of
temperature and pH corresponding to the formation of the t-CPPD
phase.10 The ionic additive was introduced into the reactor via two
routes: (i) the additive salt was dissolved at diﬀerent concentrations in
the buﬀer solution (b, placed in the reactor), or (ii) it was dissolved
into one of the reagent solutions (rs, placed in a syringe pump): in the
pyrophosphate reagent solution for experiments with the anionic
additive (S2O3
2−) or in the calcium reagent solution for experiments
with cationic additives (Mg2+, Cu2+, Fe3+, Zn2+).
The concentrations tested for each ionic additive were chosen to be
in the range of those found in human blood plasma (1 mM of
dissociated Mg2+, 0.002 to 0.04 mM Fe)34−37 or in blood components
(0.020 to 0.030 mM Zn2+ in blood plasma),38 except for sodium
thiosulfate, which is not naturally present in the human body. It is
important to note that for some of these ions, their concentrations can
vary in the human body, such as Cu2+, the concentration of which is
diﬀerent in sweat (18.10 ± 3.90 μM Cu2+ in sweat from the arm), in
serum (0.00 μM Cu2+ for a healthy patient, 0.64 ± 1.10 μM Cu2+ for
an osteoarthritic patient), and in synovial ﬂuid (1.10 ± 1.65 μM Cu2+
for an osteoarthritic patient).39
The quantities of ionic additives to be introduced into the buﬀer (b)
or a reagent solution (rs) placed in a syringe pump were calculated
with respect to the total volume of the solution within the reactor at
the end of the precipitation: 0.10 and 1.00 mM for Zn2+, Mg2+, or
Cu2+; 0.03, 0.10, and 1.00 mM for Fe3+; and 1.00 and 5.00 mM for
S2O3
2− when the additive was introduced into the buﬀer (b). When
the additive was introduced into one of the reagent solutions (rs), the
concentrations tested for each ionic additive were 0.10 and 1.00 mM.
All experiments were performed at least in duplicate.
2.3. Characterization of the Synthesized Powders. Each
synthesized sample was characterized by powder X-ray diﬀraction
(XRD), FTIR and Raman spectroscopy, and scanning electron
microscopy (SEM). In addition, elemental analyses were performed
by inductively coupled plasma optical emission spectrometry (ICP-
OES) on a solution of each sample.
The powder X-ray diﬀraction data were collected with a Bruker D8
Advance diﬀractometer equipped with a Bragg−Brentano θ−θ
geometry and a copper anode (λ (Cu Kα1) = 1.54060 Å and λ (Cu
Kα2) = 1.54439 Å). The X-ray diﬀraction patterns were obtained for a
range of 2θ angles from 5 to 50° with a step of 0.2°.
Figure 1. Standard experimental setup for the precipitation in a stirred
tank at controlled temperature, pH, ﬂow rate, and mixing.
Figure 2. XRD patterns of m-CPPD and t-CPPD reference phases and of samples synthesized in the presence of additives at various concentrations
(0.10 or 1.00 mM for Mg2+, Zn2+, or Cu2+; 0.03, 0.10, or 1.00 mM for Fe3+; and 1.00 or 5.00 mM for S2O3
2−) initially present in the buﬀer solution
(b).
A semiquantitative study was performed on the XRD data obtained
for each synthesized sample using the TOPAS software according to
the methods of Scarlett and Madsen40 and Madsen et al.41 which
allowed the determination of the relative proportion (wt %) of m-
CPPD, t-CPPD, and a-CPP phases. This method, named the Partial or
No Known Crystal Structure method (PONKCS), is a direct
approach, where the amorphous contribution to the pattern is used
to directly estimate its proportion. A ±1 wt % accuracy for the relative
weight proportion can be expected with the PONKCS method.41
FTIR spectra were recorded with a ThermoNicolet 5700 Fourier-
transform infrared spectrometer in the 4000−400 cm−1 range with 64-
scan accumulation in transmission mode and a ±4 cm−1 resolution
using powder samples in KBr pellets (2 mg of sample in 300 mg of
KBr).
Elemental analyses were performed on aqueous solutions of the
dissolved samples using ICP-OES (Ultima2 spectrometer, HORIBA
Jobin Yvon). Each sample was analyzed in triplicate.
Scanning electron microscopy (SEM) micrographs were obtained
using a Leo 435 VP microscope. The samples were silver-plated with
an evaporator (Scancoat Six, Edwards) before observation.
Thermogravimetric analyses (TGA-DTA) were performed on some
of the samples using a Setaram Setsys Evolution instrument, with a
heating rate of 5 °C per minute, starting at 25 °C up to 1000 °C.
Complementarily to the XRD analyses, for some of the synthesized
samples, further structural investigations were performed using 31P
magic-angle spinning (MAS) NMR. Data were recorded using a 700
MHz Bruker AVANCE III spectrometer, equipped with a 4 mm
Bruker MAS probe. A MAS frequency of 14 kHz was used. The
chemical shifts were referenced to H3PO4. The main purposes of these
experiments were (i) to measure the T1(
31P) relaxation times in order
to evaluate the impact of the cations added in the precipitating
medium, and (ii) to record fully relaxed 31P NMR spectra in order to
quantify the involved phases. Brieﬂy, a saturation-recovery experiment
under fast MAS was implemented as follows: saturation 31P pulses
were followed by a delay ranging from 0.25 to 720 s, and a ﬁnal 31P
90° pulse of 5 μs. Spinal-64 1H decoupling (70 kHz) was applied
during acquisition.42 Prior to all experiments, the magic angle was
carefully set in order to obtain the best 31P MAS resolution, avoiding
the reintroduction of any CSA (chemical shift anisotropy) or dipolar
interaction which would broaden the spectra. Four scans were usually
used.
3. RESULTS AND DISCUSSION
3.1. Inﬂuence of Ionic Additives Initially Present
within the Buﬀer (b) Solution: Qualitative and Semi-
quantitative XRD Study. The X-ray patterns of the CPP
reference sample (prepared in the absence of additive) and of
the CPP samples synthesized in the presence of Mg2+, Zn2+,
Fe3+, Cu2+, or S2O3
2− ions initially present at diﬀerent
concentrations in the buﬀer solution within the reactor are
shown in Figure 2. The results of the semiquantitative analysis
(relative weight proportion of m-CPPD, t-CPPD, and a-CPP
phases for all synthesized samples) of these XRD data are
reported in Table 2. We observed that the method of synthesis
in a stirred reactor at pH 3.6 and 90 °C and without additives
led to the precipitation of the t-CPPD phase (reference
compound) and that no additional crystalline phase could be
detected using XRD (as compared with the JCPDS No. 00−
041−0488 XRD reference data for the t-CPPD phase).
However, it appeared that this reference t-CPPD sample was
not fully crystallized (93 wt % of t-CPPD) and that it included a
small proportion (7 ± 1 wt %) of the a-CPP phase (Table 2).
The eﬀect of maturation time during the synthesis of t-CPPD
and m-CPPD phases has yet been investigated; the character-
ization of the precipitates formed during the synthesis from 3
min up to the end of the precipitation (about 1 h) showed that
the phases were formed from the beginning and did not evolve
(unpublished results). Additional evolution tests have been
made at 37 °C, in solution, for 1 month for t-CPPD and m-
CPPD phases, and no alteration was detected.
The composition of the samples synthesized in the presence
of ionic additives showed the characteristic peaks of t-CPPD
(especially at 10.96° ± 0.02 and 12.59° ± 0.02) and a more or
less intense additional diﬀraction peak at about 2θ = 12.03° ±
0.02 characteristic of the m-CPPD phase ((110) Bragg peak43),
indicating that this latter phase also formed when the ionic
additives tested were present, except in the case of a low
concentration of Mg2+ (0.10 mM) (Figure 2). The relative
weight percentage of m-CPPD was approximately 0% in the
absence of ionic additive, but increased from 3 ± 1 wt % up to
75 ± 1 wt % in the presence of 1.00 mM of S2O3
2− or Zn2+,
respectively (Table 2). We can also clearly observe a dose-
dependent eﬀect (by comparison of the relative peak intensities
for 0.10 and 1.00 mM of additive) for each ionic additive except
for S2O3
2−: in the case of a higher concentration (1.00 mM) of
Fe3+, Zn2+, or Cu2+ we observed that the diﬀraction peaks for
the t-CPPD phase were almost absent, indicating that the major
crystalline phase in these samples was m-CPPD (37, 75, and 60
wt %, respectively). The dose-dependent eﬀect appeared to be
less pronounced in the presence of Mg2+ than in the presence
of Fe3+, Zn2+, or Cu2+ and was negligible for S2O3
2−: in both
cases (Mg2+ and S2O3
2−) the major crystalline phase observed
remained t-CPPD (from 69 up to 90 wt %).
Furthermore, it can be noted that the relative proportion of
the amorphous phase increased signiﬁcantly in the presence of
1.00 mM of Zn2+ (20 ± 1 wt %) or Cu2+ (36 ± 1 wt %). The
greatest eﬀect was observed for 1.00 mM of Fe3+ (62 ± 1 wt
%). The presence of an amorphous phase from 5 up to 62 ± 1
wt % depending on the ionic additive present in the
precipitating medium, is supporting the observation of a
more or less important diﬀuse halo on the XRD pattern (Figure
3). Like the pure a-CPP reference compound, the fraction of a-
CPP phase detected is probably associated with around 3 to 4
water molecules.8−10
These results showed that 1.00 mM Fe3+, Zn2+, or Cu2+
induced the most signiﬁcant changes related to the presence of
the m-CPPD and a-CPP phases: the presence of 1.00 mM of
Zn2+, Cu2+, or Fe3+ ions partly inhibited the crystallization of t-
Table 2. Relative Weight Proportion (wt %) of the CPP
Phases (m-CPPD, t-CPPD, and a-CPP) Determined from
the XRD Data for the Samples Precipitated in the Presence
or Absence of Ionic Additives Initially Introduced in the
Buﬀer Solution (Denoted (b) in the Main Text)s
ionic additive concentration in the
precipitation medium
m-CPPD
(wt %)
t-CPPD
(wt %)
a-CPP
(wt %)
without additive (reference) 0 ± 1 93 ± 1 7 ± 1
[S2O3
2−] = 1.00 mM 3 ± 2 90 ± 1 7 ± 1
[S2O3
2−] = 5.00 mM 3 ± 1 89 ± 1 8 ± 1
[Mg2+] = 0.10 mM 1 ± 1 94 ± 1 5 ± 1
[Mg2+] = 1.00 mM 26 ± 1 69 ± 1 5 ± 1
[Fe3+] = 0.03 mM 4 ± 1 89 ± 1 7 ± 1
[Fe3+] = 0.10 mM 14 ± 1 80 ± 1 6 ± 1
[Fe3+] = 1.00 mM 37 ± 1 1 ± 1 62 ± 1
[Zn2+] = 0.10 mM 6 ± 1 84 ± 1 10 ± 1
[Zn2+] = 1.00 mM 75 ± 1 5 ± 1 20 ± 1
[Cu2+] = 0.10 mM 4 ± 2 93 ± 1 3 ± 1
[Cu2+] = 1.00 mM 60 ± 1 4 ± 1 36 ± 1
sAll experiments were performed in duplicate.
CPPD and favored the formation of (i) a-CPP phase (62 ± 1
wt %) in the presence of Fe3+, and (ii) m-CPPD phase (75 ± 1
wt %) in the presence of Zn2+. For the lowest concentrations of
Zn2+, Cu2+, or Fe3+ ions (0.10 mM), t-CPPD remained the
major phase in the precipitated samples.
All these results demonstrated a major eﬀect of 1.00 mM of
Cu2+, Zn2+, and Fe3+ on t-CPPD crystallization, but did not
allow the detection of pure crystalline phases of magnesium,
zinc, iron, or copper pyrophosphate that may have precipitated,
considering the limit of detection (2%) of the XRD analysis.
Assuming that all the cationic additives (A) involved in the
synthesis had precipitated as A-pyrophosphate salts, we would
have expected a contribution of 2.6% (molar) or 2.0 to 3.1 wt %
of this compound depending on the additives (Zn2+, Cu2+, or
Mg2+) or 4.0% (molar) or 3.9 wt % of iron pyrophosphate
(with Fe/Pyro = 4/3 for electrical neutrality of the solid),
which would have been detectable by XRD.
Moreover, after carefully checking the unit-cell parameters
calculated from the XRD pattern data, we can conﬁrm that
there is no signiﬁcant diﬀerence from the unit-cell parameters
of the reference CPPD phases already published.10
Further structural investigations were performed by 31P solid-
state NMR analysis to provide more information on the phases
that precipitated in the presence of additives via the chemical
shift 31P and relaxation time T1(
31P) data (see Section 3.3).
Indeed T1 (the longitudinal relaxation time) is a parameter,
which is sensitive to the potential presence of paramagnetic
ions, such as Cu2+ and Fe3+, in the precipitated CPPs.
3.2. Inﬂuence of Ionic Additives Initially Present in
One of the Reagent Solutions (rs): Qualitative and
Semiquantitative XRD Study. Figure 4 shows the XRD
patterns of CPP samples synthesized with 1.00 mM of the
selected ionic additives initially present within the cationic or
anionic reagent solution (rs). The results of the semi-
quantitative analysis (relative weight proportion of m-CPPD,
t-CPPD, and a-CPP phases for all synthesized samples) of these
XRD data are reported in Table 3.
We can observe that the presence of 1.00 mM of Mg2+ or
S2O3
2− ions did not lead to signiﬁcant changes in the sample
composition, which contained mainly t-CPPD (91 wt %), a-
CPP (6 wt %), and m-CPPD (3 wt %). The results reported in
Table 3 indicate the determinant eﬀect of the presence of 1.00
mM of Fe3+, Zn2+, or Cu2+ ions on the composition of the
synthesized samples: Zn2+ or Cu2+ both favored the formation
of m-CPPD (71 and 78 wt %, respectively), a smaller amount
of a-CPP (25 and 20 wt %, respectively) and a very low
proportion of t-CPPD (4 and 2 wt %, respectively). On the
other hand, Fe3+ completely inhibited the crystallization of the
t-CPPD and m-CPPD phases: the samples synthesized in the
presence of 1 mM of Fe3+ were mostly amorphous (98 wt %).
The number of water molecules associated with this amorphous
Figure 3. XRD patterns (for 2θ = 17−45°) of the m-CPPD and a-CPP
reference compounds and the samples synthesized in the presence of
1.00 mM Cu2+ or Fe3+ initially present in the buﬀer (b) solution. Solid
line: halo corresponding to a-CPP.
Figure 4. XRD patterns of m-CPPD and t-CPPD reference phases, and of samples synthesized in the initial presence of ionic additives in one of the
reagent solutions (rs), leading to a 1 mM ionic additive concentration in the buﬀer solution at the end of the experiment.
Table 3. Relative Weight Percentage of the CPP Phases (m-
CPPD, t-CPPD, and a-CPP) Present in the Samples
Synthesized in the Presence or Absence of Ionic Additives
Initially Introduced into the Reagent Solution (rs)
ionic additive concentration in the
medium of precipitation
m-CPPD
(wt %)
t-CPPD
(wt %)
a-CPP
(wt %)
without additive (reference) 0 ± 1 93 ± 1 7 ± 1
[S2O3
2−] = 1.00 mM 3 ± 1 91 ± 1 6 ± 1
[Mg2+] = 1.00 mM 4 ± 2 90 ± 1 6 ± 1
[Fe3+] = 1.00 mM 2 ± 1 0 ± 1 98 ± 1
[Zn2+] = 1.00 mM 71 ± 1 4 ± 1 25 ± 1
[Cu2+] = 1.00 mM 78 ± 1 2 ± 1 20 ± 1
CPP phase (3.2 ± 0.1, for 1 mM of Fe3+(rs) sample),
determined by ATG analysis, was lower than those reported for
pure a-CPP reference compound,8−10 but they were still in the
range 3−4.
In addition, we observed that no crystalline phases of
magnesium, zinc, iron, or copper pyrophosphates coprecipi-
tated. As previously indicated for the samples precipitated using
the (b) protocol, if present in the samples the A-pyrophosphate
phases would have been detectable.
As in the case of ionic additives initially present in the buﬀer
solution, presented in Figure 3, the presence of a more or less
prominent diﬀuse halo around 2θ = 30°, especially for samples
prepared in the presence of Zn2+, Cu2+, or Fe3+ in the calcium
reagent solution (data not shown) testiﬁes to the presence of
an amorphous phase.
Complementary FTIR spectroscopic analysis of the samples
formed in the presence of 1.00 mM Fe3+ was performed to
further investigate their composition. The spectra of this sample
and that of reference a-CPP10 are presented in Figure 5. All in
all, the spectra were quite comparable. The presence of the νPOP
as
and the νPOP
s vibration modes conﬁrmed the presence of
pyrophosphate groups in an amorphous phase. A slight increase
of the absorbance at 960 cm−1 (ν1PO4
as ) and 1010 cm−1 (ν4PO4
as )
seems to indicate the presence of a small proportion of poorly
or noncrystalline calcium orthophosphate.44,45 Furthermore,
the splitting of the peaks corresponding to the 4νPO3
as , νPO3
as , and
δPO3 + ρPO3 vibration modes conﬁrms the presence of a small
amount of a crystalline phase of CPPD without the possibility
to clearly identify which CPPD phase (triclinic or monoclinic)
is present due to the low proportion of this crystalline phase in
this sample (2 wt % of m-CPPD evaluated by XRD, see Table
3), and also due to important band broadening characteristic of
the presence of the a-CPP phase. Complementary analysis by
Raman spectroscopy was performed and also conﬁrms this
result (data not shown).
3.3. Complementary Elemental, Morphological, and
Structural Analyses. 3.3.1. Elemental Analyses. The results
of the elemental analysis of samples precipitated in the absence
or presence of ionic additives (A) are reported in Table 4. We
note that whatever the mode of introduction (b or rs) of the
cationic additive, the lowest A/Ca and A/P ratios (for 1 mM
Mg2+(rs): 6.7 × 10−3 and 7.0 × 10−3, respectively) were
obtained for samples precipitated in the presence of Mg2+.
These ratios were the lowest in the case of anionic additives
(A/Ca = 5.8 × 10−3 and A/P = 5.9 × 10−3 for 1.00 mM S2O3
2−
Figure 5. FTIR spectra of reference m-CPPD, t-CPPD, and a-CPP phases and of the sample synthesized in the presence of 1 mM Fe3+ present
initially in the calcium reagent solution, denoted (rs) in the main text. The diﬀerent vibrational modes of the molecules, stretching (ν), bending (δ),
and rocking (ρ), respectively, symmetric (s) or antisymmetric (as), are indicated.
Table 4. A/Ca, A/P, Ca/P, and (Ca+A)/P or Ca/(P+A) Molar Ratios Calculated with Concentrations of Ca, P, and Ionic
Additives (A) Determined by ICP-OES Analyses of the Samples Synthesized in the Presence or Absence of the Ionic Additive
Initially Present in the Reagent Solution (rs) or in the Buﬀer Solution (b)
ionic additive concentration in the precipitation medium A/Ca A/P Ca/P (Ca+A)/P Ca/(P+A)
without additive (reference) 1.03 ± 0.03 - -
1.00 mM [S2O3
2−] (rs) (5.8 ± 0.2) × 10−3 (5.9 ±1.1) × 10−3 1.01 ± 0.14 - 1.01 ± 0.14
5.00 mM [S2O3
2−] (rs) (6.0 ± 0.5) × 10−3 (6.4 ± 0.6) × 10−3 1.06 ± 0.06 - 1.06 ± 0.06
1.00 mM [S2O3
2−] (b) (5.9 ± 0.3) × 10−3 (6.2 ± 0.4) × 10−3 1.04 ± 0.10 - 1.03 ± 0.10
1.00 mM [Mg2+] (rs) (6.7 ± 0.6) × 10−3 (7.0 ± 0.6) × 10−3 1.04 ± 0.09 1.05 ± 0.10 -
1.00 mM [Mg2+] (b) (9.5 ± 2.0) × 10−3 (9.1 ± 1.9) × 10−3 0.95 ± 0.09 0.96 ± 0.10 -
1.00 mM [Fe3+] (rs) (2.7 ± 0.2) × 10−2 (3.1 ± 0.3) × 10−2 1.13 ± 0.08 1.16 ± 0.08 -
1.00 mM [Fe3+] (b) (4.9 ± 0.4) × 10−2 (3.9 ± 0.5) × 10−2 0.80 ± 0.04 0.84 ± 0.05 -
1.00 mM [Zn2+] (rs) (2.8 ± 0.5) × 10−2 (2.6 ± 0.4) × 10−2 0.95 ± 0.05 0.98 ± 0.06 -
1.00 mM [Zn2+] (b) (2.8 ± 0.1) × 10−2 (2.6 ± 0.1) × 10−2 0.93 ± 0.05 0.95 ± 0.06 -
1.00 mM [Cu2+] (rs) (2.0 ± 0.3) × 10−2 (1.9 ± 0.3) × 10−2 0.94 ± 0.06 0.96 ± 0.06 -
1.00 mM [Cu2+] (b) (3.4 ± 0.2) × 10−02 (3.0 ± 0.2) × 10−02 0.90 ± 0.03 0.93 ± 0.03 -
(rs)). For the other cationic additives, this ratio ranged between
1.9% and 3.9%, indicating a quite high introduction of the
additive into the samples, including 100% for 1 mM of Cu2+
and Fe3+ introduced in the buﬀer or Zn2+ introduced in the
reagent solution. These three samples had a-CPP compositions
of 36, 62, and 25 wt %, respectively, the highest proportions of
a-CPP found in the studied samples. Indeed, if the totality of
the additive ions involved in synthesis had precipitated in pure
CPP phases in which Ca/P = 1, we would obtain 2.6% (molar)
of additive-pyrophosphate for Zn2+, Cu2+, and Mg2+ or 4.0%
(molar) of iron pyrophosphate (with Fe/Pyro = 4/3 for
electrical neutrality of the solid).
We also observed that except in the case of Zn2+ for which
the diﬀerence in sample compositions between both protocols
(b and rs) was not signiﬁcant, for all the other additives the A/
Ca and A/P ratios were higher when the additive was
introduced in the buﬀer solution (b), which corresponded to
higher initial concentration of additives (high A/Ca or A/P
initially in the buﬀer solution, which then decreased as
precipitation occurred) (Table 4). Comparing the ionic radii
(in picometer: pm) of the cationic additives (Mg2+ (72 pm),
Cu2+ (73 pm), Fe3+ (55 pm), or Zn2+ (74 pm)) with those of
Ca2+ (100 pm), they are all smaller than calcium ions,
indicating that we should expect fairly similar behavior for
these ions upon CPP precipitation, as well as no signiﬁcant
variation in their cell parameters by XRD analysis in the case of
a limited amount of additive ions incorporated in the crystals. A
Ca/P ratio lower than 1 can be expected if the cationic
additives are incorporated into the CPP precipitate and this was
observed, except in the cases of 1.00 mM Mg2+ or Fe3+ initially
introduced in the reagent solution (Table 4). This observation
may be explained by the low inﬂuence of the presence of 1.00
mM Mg2+(rs) on the sample composition (90 wt % of t-CPPD,
6 wt % of a-CPP, and 4 wt % of m-CPPD) compared with the
reference sample (without additive: 93 wt % of t-CPPD and 7
wt % of a-CPP) leading thus to a similar Ca/P ratio for both
samples (1.04 and 1.03, respectively). On the contrary, the
strongest eﬀect on CPPD crystallization was observed in the
presence of 1 mM of Fe3+(rs) (98 wt % of a-CPP and 2 wt % of
m-CPPD) and it has been reported that some orthophosphates
can be associated with a-CPP phase,8 which could in this case
explain a Ca/P ratio slightly higher than 1.
3.3.2. Observations by Scanning Electron Microscopy.
Scanning electron micrographs of the samples precipitated in
presence of the various additives initially introduced in the
buﬀer (b) or reagent solution (rs) are presented in Figure 6.
We can observe that whatever the ionic additive involved,
except in the case of Fe3+ which will be discussed in the next
paragraph, the crystals appear to keep their acicular shapes, with
a large heterogeneity in particle sizes and agglomeration states.
Indeed, in the presence of additives, except in the case of Fe3+,
we observed ﬁner particles and more needle-like crystals, which
is a morphology characteristic of the m-CPPD phase, compared
with the reference t-CPPD phase, the crystals of which appear
thicker (parallelipipedic crystals). This feature is a general
characteristic of CPPD crystals as observed in previous works
by Gras et al.10 These observations are consistent with the m-
CPPD/t-CPPD weight ratio determined by XRD, which was
found to increase rapidly with the concentration of Mg2+, Zn2+,
or Cu2+ (Table 2 and Table 3). We also notice that the
presence of Zn2+ ions causes a marked agglomeration of the
particles of the precipitate (Figure 6). A less pronounced eﬀect
seems to appear in the presence of Cu2+. These observations
can be linked to the XRD semiquantitative results (Table 2):
high agglomeration is visible for samples with a high proportion
of a-CPP even if it was not the major phase (in presence of 1
mM of Zn2+ and 1 mM of Cu2+initially introduced in the buﬀer
solution).
The case of samples precipitated in the presence of 1 mM
Fe3+ is considered separately, as the a-CPP phase was the major
phase in these samples (Table 2 and Table 3). In agreement
with the XRD data, we can see on Figure 6 that the acicular
morphology of the CPPD crystals was no longer visible for
samples precipitated in the presence of 1.00 mM Fe3+
introduced in the calcium reagent solution (rs; 98 wt % of a-
CPP), whereas a few particles with the acicular morphology
Figure 6. SEM micrographs of the crystals of the reference t-CPPD
phase and of samples precipitated in the presence of 1.00 mM Mg2+,
1.00 mM Zn2+, 1.00 mM Cu2+, or 1.00 mM Fe3+ introduced in the
buﬀer (b) or in the reagent solution (rs).
were still visible for samples precipitated in the presence of 1.00
mM of Fe3+ introduced in the buﬀer solution (b; 62 wt % of a-
CPP) (Figure 6 and Tables 2 and 3). The a-CPP phase showed
quite well dispersed and smooth, round particles with a
diameter of about 20 μm. This a-CCP phase morphology was
diﬀerent from that described by Gras et al.10 which contained
smaller (less than 1 μm) round, agglomerated particles.
Further structural investigations using solid-state NMR were
performed to shed some light on the possible mechanism of
action of some of these ionic additives.
3.3.3. Structural Analyses by 31P Solid-State NMR Spec-
troscopy. As explained previously, none of the characterization
methods used so far allowed a clear identiﬁcation of the
dopants (cationic additives) in one or the other of the mineral
phases identiﬁed, due principally to the low amount of dopant
species. The determination of T1(
31P) (spin−lattice) relaxation
times could give an answer to this important question.
Generally speaking, the observed T1 in solid-state NMR are
strongly dependent on the presence of paramagnetic species,
which has been shown to considerably reduce their values.
Thus, this method is especially useful for paramagnetic dopants
like Cu2+ and Fe3+, whereas diamagnetic species such as Zn2+
and Mg2+ are expected to produce no noticeable eﬀect (such
cations are introduced in very small amounts, and the natural
abundances of 25 Mg and 67Zn, which are quadrupolar nuclei,
are <10%).
The 31P MAS spectrum of the t-CPPD reference phase is
presented in Figure 7. As previously observed by Gras et al.,9 t-
CPPD (labeled t in Figure 7) is characterized by two sharp
peaks located at −5.14 and −6.24 ppm. The observation of two
31P resonances is in full agreement with the crystallographic
data as reported in previous publications.9 Studying the
spectrum in detail, one can observe the presence of two very
minor components at −7.5 and −9.96 ppm. They correspond
to a-CPP (labeled a in Figure 7) and m-CPPD (labeled m in
Figure 7), respectively (m-CPPD is also characterized by a
second resonance at −6.30 ppm, which here is superimposed
onto one of the peaks of the t-CPPD phase). These side phases
were considered here as negligible. T1(
31P) = 76.3 s for t-CPPD
(Table 5). m-CPPD is characterized by two resonance peaks
centered at −5.91 and −9.68 ppm. T1(
31P) = 96.0 s for m-
CPPD. In the case of a-CPP, a featureless broadened
component is observed at ∼−5 ppm, exhibiting T1(
31P) =
29.5 s.
The 31P MAS NMR spectra of the samples obtained in the
presence of 1.00 mM Cu2+ initially present in the buﬀer (b) or
in the reagent solution (rs) are reported in Figure 8. When
comparing these spectra with those of the t-CPPD, m-CPPD,
and a-CPP reference samples, it is obvious that the spectra of
the Cu2+-doped samples exhibit m-CPPD as the major phase,
conﬁrming the XRD data (Table 2 and Table 3). The 31P
isotropic chemical shifts are centered at −6.44 and −10.24
ppm, slightly shielded when compared with the m-CPPD
reference (Table 5). This variation may be attributable to the
presence of Cu2+ cations in the sample, which was conﬁrmed by
ICP-OES elemental analysis: Cu/Ca (rs) and Cu/P (rs) are
both around 2 × 10−2; Cu/Ca (b) and Cu/P (b) are both
around 3 × 10−2 (Table 4). A deconvolution of the spectra is
also presented in Figure 8. t-CPPD was present as a minor
component, as well as a much broader component, which could
be safely assigned to an amorphous phase. This amorphous
component is rather nonsymmetric in contrast to the one
observed for nondoped a-CPP (consequently, two components
were used in the ﬁnal deconvolutionthey are both indicated
by the notation “a” in Figure 8). We did not attempt to further
analyze the shape of this particular resonance, but used it as a
ﬁxed model for spectral deconvolution and quantitative
analyses (Table 5). The resulting data are in good agreement
with the results obtained by semiquantitative XRD analysis
(Table 2 and Table 3). Even if the semiquantitative XRD data
provide results in wt % and those of solid-state NMR in molar
% of the CPP phases, we can globally compare both data, as the
CPP phases involved in all samples have the same or quite the
same molecular weight (2 water molecules for t-CPPD and m-
CPPD and between 3 and 4 associated with a-CPP phase).
Finally, we note the presence of a broad component centered
at ∼−2.0 ppm. The intensity of this particular component is
small but measurable. It was even broader when Cu2+ was
introduced in the buﬀer ((b) protocol). At this stage, two
distinct assignments can be proposed for this broadened
component: (i) orthophosphates, such as those that can be
obtained as side products of the partial hydrolysis of
pyrophosphates,9 or (ii) pyrophosphates exhibiting shifted
Figure 7. 31P MAS NMR spectra (decoupled from 1H during the
acquisition) of the reference samples t-CPPD, m-CPPD, and a-CPP
(synthesized without additives). The diﬀerent components of the MAS
spectra are labeled as follows: t (t-CPPD), m (m-CPPD), and a (a-
CPP).
Table 5. T1(
31P) Relaxation Time Measured by Saturation Recovery for Each Peak Identiﬁed in the 31P MAS NMR Spectra of
Samples Synthesized in the Presence (or Absence) of Cu2+ or Fe3+ Ions Introduced in the Calcium Reagent Solution (rs) or in
the Buﬀer (b)a
Reference Samples
Figure 7
m-CPPD reference
δ (ppm) −5.91 −9.68
line width (ppm) 0.68 0.63
relaxation time T1 (s) 96.0 (±0.4)
t-CPPD reference
δ (ppm) −5.14 −6.24
line width (ppm) 0.55 0.61
relaxation time T1 (s) 76.3 (±5.8)
a-CPP reference
δ (ppm) ∼ −5
line width (ppm) 1.1
relaxation time T1 (s) 29.5 (±2.7)
Samples Precipitated in the Presence of Ionic Additive
components t t/m m sPP a
1 mM [Cu2+] (rs)
δ (ppm) −5.41 −6.44 −10.24 ∼−2.0 −7.6/−9.2
line width (ppm) 0.58 0.52 0.59 3.0 1.1/1.8
relaxation time T1 (s) 2.0 ± 0.3 2.0 ± 0.3 ∼4
area (relative percentage) (%) 4 46 37 2 6/5
1 mM [Cu2+] (b)
δ (ppm) −5.40 −6.43 −10.23 ∼−1.5 −7.9/−9.2
line width (ppm) 0.89 0.59 0.53 6.4 1.4/2.2
relaxation time T1 (s) 2.6 ± 0.3 2.6 ± 0.3 ∼4
area (relative percentage) (%) 6 33 26 15 13/7
1 mM [Fe3+] (rs)
δ (ppm) −9.9 ∼1 ∼−7.5
line width (ppm) 1.6 ∼4 ∼6
relaxation time T1 (s) 3.3 ± 0.7 <1
area (relative percentage) (%) 7 12 81
1 mM [Fe3+] (b)
δ (ppm) −6.13 −9.98 ∼1 −7.8
line width (ppm) 0.70 0.73 ∼3 ∼6
relaxation time T1 (s) <1 <1 <1
area (relative percentage) (%) 22 22 3 53
1 mM [Zn2+] (rs)
δ (ppm) −5.52 −6.55 −10.35 −7.3/−9.2
line width (ppm) 0.58 0.67 0.66 2.49/1.76
relaxation time T1 (s) 43.4 ± 3.0 49.7 ± 7.3 ∼12
area (relative percentage) (%) 3 35 32 18/12
1 mM [Zn2+] (b)
δ (ppm) −5.47 −6.51 −10.31 −7.2/−9.1
line width (ppm) 0.50 0.70 0.66 1.4/1.8
relaxation time T1 (s) 74.0 ± 6.2 93.7 ± 12.5
area (relative percentage) (%) 3 42 35 9/11
Components t t m m a
1 mM [Mg2+] (rs)
δ (ppm) −5.57 −6.67 −7.7 −10.35 −6.03
line width (ppm) 0.59 0.70 1.66 0.84 0.89
relaxation time T1 (s) 25.8 ± 2.8 27.7 ± 3.0
area (relative percentage) (%) 43 49 5 3
1 mM [Mg2+] (b)
δ (ppm) −5.56 −6.63 −9.28 −10.33 −7.97
line width (ppm) 0.59 0.74 1.44 0.64 1.72
relaxation time T1 (s) 104.4 ± 29.7 65.2 ± 6.1 35.3 ± 6.8 65.8 ± 7.9
area (relative percentage) (%) 29 53 2 16
aIsotropic chemical shifts, line widths, and relative molar % are given as well. t: t-CPPD, m: m-CPPD, a: a-CPP, sPP: shifted calcium
pyrophosphates.
δiso(
31P) due to the paramagnetic eﬀect of Cu2+ cations. From
the NMR point of view, 31P INADEQUATE MAS experiments
should allow deﬁnite assignments,8 as this double quantum
(DQ)-based experiment is sensitive to pyrophosphate groups
only. We did not attempt to implement this sequence, as the
intensity of the involved resonance was very small. However,
such a broad component was not observed at all in the case of
diamagnetic cations, namely, Zn2+ and Mg2+ (Figures 10 and
11, respectively). Moreover, it is clear from Figure 8 that the
broadening is more pronounced in the (b) protocol than in the
(rs) protocol. We recall here that Cu/P (rs) < Cu/P (b). In
summary, we suggest that the broad component centered at
∼−2.0 ppm can be assigned safely to pyrophosphate groups in
relatively close vicinity to the paramagnetic centers.46 Indeed,
such a component is observed on the 31P MAS NMR spectra.
Even if FTIR spectroscopy was able to distinguish
orthophosphate from pyrophosphate groups (for instance, in
the case of Fe3+; see Figure 5), the broadening and overlapping
of the vibrational bands would exclude deﬁnite assignments at
this stage. The complementary roles of solid state NMR
spectroscopy, X-ray diﬀraction and vibrational spectroscopies
characterization techniques are demonstrated here.
Considering the T1(
31P) data, we focused here only on the
major m-CPPD phase, and found that T1(
31P) ≅ 2.3 s for both
samples (on average). When compared with the reference m-
CPPD phase, one observes a drastic reduction of the 31P
longitudinal relaxation time. This can be safely attributed to the
presence of the paramagnetic Cu2+ cations within the m-CPPD
structure. Indeed, it is well established that paramagnetic ions
usually lead to a very eﬃcient pathway for nuclear
relaxation.46−50 Two relaxation mechanisms can be considered,
namely, a through-space dipolar coupling between electrons
and nuclei and a through-bond electronic interaction (Fermi
contact). Both are usually present. The eﬀect of paramagnetism
on the NMR resonances can be summarized as the following:
(i) a loss of signal is observed for those nuclei in close vicinity
to the paramagnetic centers, (ii) line widths can broaden
signiﬁcantly, (iii) nuclear longitudinal T1 values are usually
strongly shortened, and (iv) paramagnetic shifted peaks can be
observed directly on the NMR spectrum. Very recently,
McCarty and Stebbins51 performed an in-depth study of the
eﬀect of paramagnetic cations such as Ni2+ and Co2+ on the
17O, 25 Mg, and 43Ca MAS NMR spectra of CaO, MgO, and
CaO.
Though present as a minor component, T1(
31P) ≅ 4 s was
estimated for the a-CPP component. No attempt was made to
derive the T1(
31P) data for t-CPPD (t) and the shifted
pyrophosphates (sPP) as the corresponding intensities were
intrinsically small.
The 31P MAS NMR spectra of the samples obtained in the
presence of 1 mM Fe3+ initially present in the buﬀer (b) or in
the reagent solution (rs) are reported in Figure 9. All relevant
isotropic chemical shifts and T1(
31P) data are reported in Table
5. In the case of the (b) protocol, there are similarities with the
results for the Cu2+-doped samples. Indeed, m-CPPD and a-
CPP were clearly obtained as major phases, but with a diﬀerent
molar ratio compared with the Cu2+ case. This result is in good
agreement with the XRD data (Table 2 and Table 3).
In the case of the (rs) protocol, a broad spectrum was
obtained, exhibiting two main components: shifted pyrophos-
phates, sPP; and amorphous pyrophosphates, a (Figure 9). A
very small amount (∼4%) of another phase (∼−9.9 ppm) was
faintly detected.
This 31P isotropic chemical shift is in agreement with the
presence of m-CPPD as a minor phase, as shown by powder
XRD (Table 3).
In other words, Fe3+ is able to inhibit almost completely the
crystallization of CPPD phases (m and t) when using the (rs)
protocol. As already observed in the case of Cu2+-doped
samples, a drastic reduction of T1(
31P) was observed for both
m-CPPD and a-CPP phases. This shows again that Fe3+ cations
are inserted into the m-CPPD and a-CPP phases.
In the case of Fe3+ ((b) protocol), we further observe that
the content of a-CPP is much larger than in the case of Cu2+
(Figure 8). This observation is in full agreement with the
semiquantitative XRD data mentioned above (62 wt % of a-
CPP phase in the case of Fe3+).
The 31P MAS NMR spectra of the samples obtained in the
presence of 1.00 mM Zn2+ and Mg2+ (diamagnetic species)
initially present in the buﬀer (b) or in the calcium reagent
solution (rs) are reported in Figures 10 and 11, respectively. All
relevant isotropic chemical shifts and T1(
31P) data are reported
in Table 5. In the case of Zn2+ (Figure 10), there are similarities
with the results of the Cu2+-doped samples. Indeed, m-CPPD
and a-CPP were clearly obtained as the major phases but with a
diﬀerent molar ratio when compared with the Cu2+ case. This
result is in good agreement with the XRD data (Table 2 and
Table 3). Furthermore, the molar proportions of the diﬀerent
phases reported in Table 5 are in good agreement with the
XRD data (Table 2 and Table 3) and conﬁrm that m-CPPD
and a-CPP are indeed obtained as the major phases.
Figure 8. 31P MAS NMR spectra (decoupled from 1H during the
acquisition) of samples synthesized in the presence of 1.00 mM Cu2+
introduced in the buﬀer (b) or in the calcium reagent solution (rs).
The relaxation delay after the train saturation of the 31P channel was
incremented from the bottom to the top of the spectra (saturation−
recovery). The diﬀerent components of MAS spectra are labeled as
follows: t (t-CPPD), m (m-CPPD), a (a-CPP), and sPP (shifted
calcium pyrophosphates).
In the case of the (rs) protocol (Zn2+), the amorphous (a)
contribution is characterized by two components as observed
above (Figure 10). Furthermore, a small contribution of t-
CPPD is evidenced as well. Finally, a negligible resonance is
observed at ∼0 ppm.
As already observed in the case of Cu2+ doped samples, a
signiﬁcant reduction of T1(
31P) was observed for both the m-
CPPD (∼45.0 s) and a-CPP (∼12.0 s) phases (we mention
here that T1(
31P) = 96.0 and 29.5 s for reference m-CPPD and
a-CPP, respectively). However, this reduction is not as
pronounced as in the case of the paramagnetic ions of Cu2+.
In this case, any eﬀect of paramagnetic relaxation is excluded.
We believe that Zn2+ cations enter the m-CPPD structure as
well as a-CPP, leading to local defects and consequently to the
subsequent decrease of T1(
31P).
When comparing the spectra obtained in the case of Mg2+
with the t-CPPD, m-CPPD, and a-CPP references (Figure 11),
it is obvious that the spectra of the Mg2+-doped samples exhibit
t-CPPD as the major phase and m-CPPD as a minor one in the
case of the (b) protocol. This result is in good agreement with
the XRD data (Tables 2 and 3), and the molar proportions of
the diﬀerent phases reported in Table 5 are in good agreement
with XRD as well. The 31P isotropic chemical shifts are
centered at −5.70, −6.50, and −10.34 ppm, slightly shielded
when compared with the reference phases. This variation may
be attributable to the presence of Mg2+ cations which was
conﬁrmed by ICP-OES elemental analysis: Mg/P (rs) = (7.0 ±
0.6) × 10−3; Cu/P (b) = (9.1 ± 1.9) × 10−3 (Table 4). As
already observed in the case of the Zn2+-doped samples, a
reduction of T1(
31P) (in the presence of Mg2+) was observed
for t-CPPD in the (rs) protocol and m-CPPD in the (b)
protocol as well. Recently, Gras et al.43 reported some
similarities between the m-CPPD and t-CPPD phase structures
and those of other dihydrated pyrophosphate phases involving
Figure 9. 31P MAS NMR spectra (decoupled from 1H during the
acquisition) of samples synthesized in the presence of 1.00 mM Fe3+
introduced in the buﬀer (b) or in the calcium reagent solution (rs).
The relaxation delay after the train saturation of the 31P channel was
incremented from the bottom to the top of the spectra (saturation−
recovery). The diﬀerent components of MAS spectra are labeled as
follows: m (m-CPPD), a (a-CPP), and sPP (shifted pyrophosphates).
Figure 10. 31P MAS NMR spectra (decoupled from 1H during the
acquisition) of samples synthesized in the presence of 1.00 mM Zn2+
introduced in the buﬀer (b) or in the calcium reagent solution (rs). t
(t-CPPD), m (m-CPPD), a (a-CPP).
other divalent metal cations, such as Mg2+, Mn2+, Fe2+, or Co2+,
which support our results suggesting the introduction of
magnesium in the CPPD phase structures.
These experiments using the same ionic additive introduced
in the buﬀer or in the reagent solution demonstrate that the
initial concentration of the additive and its distribution in the
reactor combined with the supersaturation level are crucial
parameters.
Concerning the inhibition of the t-CPPD crystallization by
Fe3+ ions, there may be a competition between iron
pyrophosphate and calcium pyrophosphate precipitation, or
Fe3+ may be adsorbed on the crystal and block some of the
growth sites (the Fe/Ca atomic ratio ranged between 2.7% and
4.9%; Table 4).
The use of S2O3
2− ion as an additive has no notable eﬀect on
the t-CPPD formation.
At this stage, it is important to recall that the m- and t-CPPD
phases are those that have been identiﬁed in vivo, while we are
attempting to explain some of their behaviors observed in vitro.
The medium of precipitation is highly supersaturated at the
beginning of the synthesis. In the presence of additives, it is
possible that the most unstable phase (a-CPP) is formed ﬁrst,
then evolves into m- or t-CPPD. The formation of a dihydrate
phase instead of another may be due to kinetics, potentially
modiﬁed by the presence of additives in the precipitation
medium. This seems to be consistent with the fact that in vitro,
the a-CPP phase could be a precursor of the m- and t-CPPD
phases. Another hypothesis is that the less stable crystalline
dihydrated phase (m-CPPD) could be formed ﬁrst, and then
evolve into t-CPPD. In this case, the ionic additives studied
here would stabilize the m-CPPD phase and therefore prevent
it from evolving toward the t-CPPD phase. This assumption is
consistent with the eﬀect identiﬁed in this study for Mg2+, Zn2+,
and Cu2+ cations. These ions promote the formation of m-
CPPD instead of t-CPPD by replacing Ca2+ in the structure.
That eﬀect is especially strong for high initial concentrations of
these ions at the beginning of the precipitation of CPP ((b)
protocol). A potential excess of certain ions in arthritic joints
could be a precursor and/or aggravating factor for the
formation of CPPD crystals and the inﬂammatory response.
To explore this assumption, it could be interesting to correlate
medical analyses of the osteoarticular ﬂuid compositions in
osteoarthritic patients who also suﬀer from diseases caused by
ionic imbalance, such as Menke’s or Wilson’s disease aﬀecting
copper levels in the body.52 Furthermore, the used of Fe3+ ions
to prevent the precipitation of CPPD crystals has yet to be
explored in physiological conditions.
■ CONCLUSION
Calcium pyrophosphate dihydrate polymorphs (m-CPPD and
t-CPPD: Ca2P2O7·2H2O) detected in the joints of arthritic
patients are known to be highly inﬂammatory. Understanding
their formation and trying to minimize their development are
routes to reduce the pain caused or even to cure the disease.
Two main steps were analyzed in this study to achieve this
goal: the ability to produce these crystals in vitro, outside the
human body, to study their nucleation and growth phenomena
on the one hand, and testing ionic additives likely to have an
inhibitory action on CPPD formation on the other hand.
A stirred-batch reactor under controlled pH and temperature
was implemented to prepare almost pure t-CPPD, m-CPPD,
and a-CPP (amorphous) phases by simultaneously adding, at
controlled ﬂow rates, a potassium pyrophosphate reagent
solution, and a calcium nitrate reagent solution into an
ammonium acetate buﬀer solution. This method is fast and
reproducible and produces adequate quantities of pure
products in vitro.
These phases were characterized in detail by using X-ray
diﬀraction, FTIR spectrometry, 31P solid-state nuclear magnetic
resonance, scanning electron microscopy, and elemental
analysis by inductively coupled plasma spectrometry. The
addition of one type of ionic additives ionic additives (Mg2+,
Cu2+, Fe3+, Zn2+, and S2O3
2−) in the reactor during the
precipitation of CPPD was tested. These additives can inﬂuence
the obtained phase.
Figure 11. 31P MAS NMR spectra (decoupled from 1H during the
acquisition) of samples synthesized in the presence of 1.00 mM Mg2+
introduced in the buﬀer (b) or in the calcium reagent solution (rs). t
(t-CPPD), m (m-CPPD).
When the t-CPPD phase was synthesized in the presence of
ionic additives, the results showed that instead of pure t-CPPD,
the m-CPPD phase formed simultaneously for all the tested
ionic additives, except in the case of low concentrations of
Mg2+. We also observed a dose-dependent eﬀect: the higher the
amount of additives, the higher the proportion of m-CPPD in
the obtained mixture. Furthermore, for some additives, like
Zn2+, Cu2+, and Fe3+, the relative proportion of the amorphous
phase increased signiﬁcantly in the mixture. The additive can
also change the morphology of the obtained particles, leading
to more or less agglomerated crystals. The use of S2O3
2− ions as
an additive has no notable eﬀect on the formation of t-CPPD.
NMR analysis has allowed us to advance some interpretation
of the modes of action of the cationic additives tested that can
be adsorbed or inserted in the crystal lattice. In vitro, the a-CPP
phase may be a precursor of the m- and t-CPPD phases.
Another hypothesis is that the less stable crystalline dihydrated
phase (m-CPPD) may be formed ﬁrst, and then evolve into t-
CPPD. In this case, the ionic additives studied here would
stabilize the m-CPPD phase and therefore prevent it from
evolving toward the t-CPPD phase. As ionic additives may
change the CPPD nucleation and crystal growth processes, we
recently engaged to study CPPD crystallization at constant
supersaturation with diﬀerent CPPD seeds to understand better
these eﬀects.
This study contributes to understanding the role some trace
elements can have in CPP crystal formation occurring in
pseudogout and in associated diseases like hypomagnesaemia
(low magnesium), Wilson’s disease (copper excess), and
hemochromatosis (iron excess).
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.cgd.6b01128.
Raman spectra of reference m-CPPD, t-CPPD, and a-
CPP phases and of the sample synthesized in the
presence of 1 mM Fe3+ present initially in the calcium
reagent solution (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: christele.combes@ensiacet.fr. Tel: +33 (0)5 34 32 34
09.
ORCID
Christel̀e Combes: 0000-0001-5009-1973
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
The authors thank the Agence Nationale de la Recherche
(CAPYROSIS project − ANR-12-BS08-0022-01) for the
ﬁnancial support of this research work and Pr F. Liote ́ and Pr
H−K Ea from Bioscar U1132 Laboratory (Hôpital Lariboisier̀e,
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